TTX MC 138
Alternative Names: TTX-MC-138Latest Information Update: 17 Oct 2025
At a glance
- Originator TransCode Therapeutics
- Class Antineoplastics; Antisense oligonucleotides; Immunotherapies
- Mechanism of Action Cell death stimulants; Gene silencing; MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Colorectal cancer; Glioblastoma; Osteosarcoma; Pancreatic cancer; Small cell lung cancer; Triple negative breast cancer; Unspecified
Most Recent Events
- 14 Oct 2025 Preliminary pharmacodynamics and adverse events data from a phase-Ia/II trial in Solid tumours released by TransCode Therapeutics
- 08 Oct 2025 Preclinical trials in Unspecified (Combination therapy) in USA (unspecified route) (TransCode pipeline, October 2025)
- 08 Oct 2025 TransCode Therapeutics plans a phase-II trial (IV),